AbbVie beats Q1 2026 earnings, raises full-year forecast

AbbVie raised its full-year adjusted net forecast aft first-quarter results exceeded expectations, driven by beardown request for its newer immunology drugs Skyrizi and Rinvoq arsenic income of erstwhile apical seller Humira continued to fall.

Raising its outlook, the institution acceptable a caller full-year adjusted diluted net people of $14.08 to $14.28 per share, compared with its erstwhile guidance of $13.96 to $14.16. First-quarter adjusted diluted net per stock came successful astatine $2.65, an summation of 7.7% from the aforesaid play a twelvemonth earlier. On a GAAP basis, diluted EPS was $0.39, a alteration of 45.8%.

First-quarter nett revenues reached $15 billion, an summation of 12.4% connected a reported basis. Analysts had projected $14.72 billion, according to Reuters.

Immunology portfolio income roseate 16.4% to $7.29 billion. Quarterly gross for Skyrizi totaled $4.48 billion, a 30.9% year-over-year gain, and Rinvoq contributed $2.12 billion, reflecting 23.3% growth. Humira, which mislaid U.S. patent extortion successful 2023 and has since contended with an influx of lower-cost biosimilars, saw planetary revenues diminution 38.6% to $688 million.

Neuroscience revenues climbed 26% to $2.88 billion, making it different country of notable spot for the quarter. For the archetypal time, Global Botox Therapeutic income surpassed $1 cardinal successful a azygous quarter, coming successful astatine $1.009 billion, a 16.5% increase. The schizophrenia cause Vraylar generated $905 million.

The aesthetics portfolio grew 7.6% to $1.19 billion. Botox Cosmetic income roseate 20.2% to $668 million, portion Juvederm revenues were $232 million, an summation of 0.4% connected a reported basis.

Oncology revenues were $1.63 billion, astir level compared with the anterior year. Venclexta income grew 15.7% to $770 million, portion Imbruvica revenues fell 24.7% to $556 million.

"We are disconnected to an fantabulous commencement successful 2026, with first-quarter results exceeding our expectations," CEO Robert A. Michael said successful a statement.

The company's updated guidance includes an unfavorable interaction of $0.41 per stock related to acquired in-process R&D and milestone expenses incurred done the archetypal quarter. AbbVie said the forecast excludes immoderate further specified expenses that whitethorn beryllium incurred beyond the archetypal quarter, arsenic those cannot beryllium reliably forecast.

Investors responded positively to the report, sending AbbVie shares up astir 2% to 3% successful premarket trading. Heading into the session, the banal had shed 13.5% connected the year.